Loading...
XNAS
ILMN
Market cap39bUSD
Oct 20, Last price  
267.93USD
1D
0.05%
1Q
36.43%
Jan 2017
110.88%
IPO
1,278.68%
Name

Illumina Inc

Chart & performance

D1W1MN
XNAS:ILMN chart
P/E
47.60
P/S
9.33
EPS
5.63
Vol. 1Y
48.42%
Shs. 5Y
1.06%
Rev. 5Y
6.02%
Div Yld LY
—
Div Yld TTM
—
Revenues
4.34b
-0.78%
1,148,516,0001,148,516,0001,421,178,0001,421,178,0001,861,358,0001,861,358,0002,219,762,0002,219,762,0002,398,373,0002,398,373,0002,752,000,0003,333,000,0003,333,000,0003,543,000,0003,239,000,0004,526,000,0004,584,000,0004,504,000,0004,372,000,0004,338,000,000
Net income
850m
P
151,254,000151,254,000125,308,000125,308,000353,351,000353,351,000461,559,000461,559,000462,649,000462,649,000726,000,000826,000,000826,000,0001,002,000,000656,000,000762,000,000-4,404,000,000-1,161,000,000-1,223,000,000850,000,000
CFO
1.08b
+28.91%
291,873,000291,873,000386,421,000386,421,000501,271,000501,271,000659,596,000659,596,000687,238,000687,238,000875,000,0001,142,000,0001,142,000,0001,051,000,0001,080,000,000545,000,000392,000,000478,000,000837,000,0001,079,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1998 and headquartered in San Diego, California, Illumina, Inc. delivers cutting-edge sequencing and array technologies crucial for genetic and genomic analysis. The company's comprehensive offerings empower clients across numerous sectors, facilitating the integration of genomic solutions into both research and clinical applications. These span critical fields such as life sciences, oncology, reproductive health, and agriculture. Illumina's product suite encompasses analytical instruments and their associated consumables, complemented by a range of services including genotyping, sequencing, instrument support contracts, development and licensing partnerships, and cancer detection testing. Its extensive customer base comprises genomic research centers, academic bodies, government laboratories, hospitals, pharmaceutical and biotechnology companies, commercial molecular diagnostic labs, and consumer genomics enterprises. The company directly distributes its products across North America, Europe, Latin America, and the Asia-Pacific region, while also leveraging life-science distributors to reach markets in Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Related entities

Subsidiaries (5)
ILLUMINA CAMBRIDGE LIMITED
Illumina Singapore Pte. Ltd.
ILLUMINA INDIA BIOTECHNOLOGY PRIVATE LIMITED
ILLUMINA PRODUCTOS DE ESPANA SL
Illumina Switzerland GmbH

Key people

Scott Gottlieb
Independent Chairman of the Board · since 2025
Jacob Thaysen
Chief Executive Officer, Director · since 2023
Ankur Dhingra
Chief Financial Officer · since 2024
Patricia Leckman
Chief People Officer · since 2023
Steven Barnard
Chief Technology Officer · since 2023
Kevin Pegels
Chief of Global Operations · since 2021
Jakob Wedel
Chief Strategy and Corporate Development Officer · since 2024
Scott Davies
Chief Legal Officer, Secretary · since 2025
Independent Director · since 2016
Independent Director · since 2017
Independent Director · since 2012
Independent Director · since 2017
Independent Director · since 2025
Independent Director · since 2024
Philip Schiller
Independent Director · since 2017
Independent Director · since 2019
Independent Director · since 2023
IPO date
Jun 28, 2000
Employees
11,500
Domiciled in
US
Incorporated in
US
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
5200 ILLUMINA WAY
SAN DIEGO, CA 92122
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑002021‑002019‑122018‑122018‑122017‑122017‑002016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT